Cargando…
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro
Delayed-release dimethyl fumarate (also known as gastro-resistant dimethyl fumarate), an oral therapeutic containing dimethyl fumarate (DMF) as the active ingredient, is currently approved for the treatment of relapsing multiple sclerosis. DMF is also a component in a distinct mixture product with 3...
Autores principales: | Brennan, Melanie S., Matos, Maria F., Li, Bing, Hronowski, Xiaoping, Gao, Benbo, Juhasz, Peter, Rhodes, Kenneth J., Scannevin, Robert H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368598/ https://www.ncbi.nlm.nih.gov/pubmed/25793262 http://dx.doi.org/10.1371/journal.pone.0120254 |
Ejemplares similares
-
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data
por: Landeck, Lilla, et al.
Publicado: (2018) -
The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes
por: Brennan, Melanie S., et al.
Publicado: (2017) -
Dimethyl Fumarate Induces Glutathione Recycling by Upregulation of Glutathione Reductase
por: Hoffmann, Christina, et al.
Publicado: (2017) -
Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)